In 2019, the FDA classified the psychoactive chemical compound found in certain strains of medicinal mushrooms as a “breakthrough therapy” to treat severe treatment-resistant depression. This compound is also being researched as a therapy for a variety of different ailments including Alzheimer’s, PTSD and end-of-life anxiety and depression. As a certified benefit corporation, MYYCO is partnered with several high profile research centers that are working on this exciting new frontier of therapy. Many of these research centers are preparing for phase 3 trials that could quickly lead to publicly available medicines. These phase 3 trials are expensive (upwards of $20 million) and the entire process of introducing a new medicine into the pharmaceutical marketplace can cost close to $2 billion. MYYCO donates all profits to the 501(c)(3) research centers working to bring the healing power of mushrooms to those who need it.